ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive AMI, and these were carried out in the era before AMI was diagnosed with biomarkers and prior to treatment with coronary angioplasty, use of antithrombotic agents and high intensity statins, and angiotensin-aldosterone system inhibitors.

ACC 2024

The aim of this multicenter, randomized study was to assess the potential benefit of treatment with beta-blockers after AMI in patients with conserved left ventricular systolic function in the current era of percutaneous treatment and medical treatment. 

The primary outcome was a combination of all-cause death and non-fatal AMI. Secondary end point was a combination of all-cause death, AMI and hospitalization for cardiac failure. There was a safety end point including hospitalization for bradyarrhythmia, hypotension or syncope, hospitalization for asthma or COPD and hospitalization for stroke. 

5020 patients were randomized; 2508 to receiving beta-blockers (metoprolol or bisoprolol) and 2512 for conventional treatment. Mean age was 65 and most were men. Mean followup was 3.5 years. 35% of patients presented ST elevation AMI. 17% presented left main and three vessel disease, and most received percutaneous coronary intervention (PCI) (96%), while the remaining 4% underwent myocardial revascularization surgery (CABG).

Read also: ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus.

The primary outcome resulted 7.9% for the beta-blocker group vs. 8.3% for the conventional treatment group (HR 0.96; CI 95% 0.79-1.16; p=0.64). There were no differences in secondary and safety end points.

Conclusion 

Among patients with acute myocardial infarction undergoing early coronary angiography with conserved left ventricular ejection fraction (≥50%), treatment with beta-blockers at long term did not present lower risk of all cause death or new AMI or new myocardial infarction vs. no beta-blockers. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Beta-blockers after Myocardial Infarction and Preserved Ejection Fraction.

Reference: Troels Yndigegn et al ACC 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....